Key Highlights

  • Rivian (NASDAQ:RIVN) gained about 4 percent to 5 percent after hours on October 29, 2026, following a third-quarter loss of USD 0.48 per share, narrower than consensus. Revenue came to USD 2.155 billion, up 38 percent, and the low end of delivery guidance was lifted to 67,000 to 70,000 vehicles.
  • Eli Lilly (NYSE:LLY) surged 6.7 percent to USD 1,374.21 on October 29, 2026 after lifting 2026 revenue guidance to USD 91 billion to 92 billion. Third-quarter revenue reached USD 24.4 billion versus USD 22.6 billion expected, and adjusted Earnings came to USD 7.48 per share.
  • According to one account, Insmed (NASDAQ:INSM) rose 16 percent on October 29, 2026 after topping revenue expectations and lifting its full-year guidance. Revenue, earnings and guidance figures were unavailable, so the scale of the raise cannot be determined.
  • Crocs (NASDAQ:CROX) jumped about 25 percent on October 29, 2026, reaching its loftiest level in over two years. HeyDude revenue grew 6.1 percent to USD 170 million, and the company lifted its 2026 guidance for a third time.

Rivian (NASDAQ:RIVN): Narrower loss and delivery guide

Rivian (NASDAQ:RIVN) released third-quarter results after the close on October 29, 2026. The loss came to USD 0.48 per share, revenue reached USD 2.155 billion, up 38 percent from a year earlier, and the company delivered 19,248 vehicles. Management raised the low end of full-year delivery guidance, now 67,000 to 70,000 vehicles, and lifted its adjusted EBITDA guide by USD 100 million at the midpoint. The shares rose about 4 percent to 5 percent after hours. Two published accounts confirm the results, but they differ on the consensus loss, at USD 0.61 and USD 0.64, so the beat is labeled as narrower than expected rather than given as a precise figure. Delivery guidance is a range, and raising its low end moves the range upward, which signals more confidence in the weakest case. Adjusted EBITDA measures operating profit before interest, taxes, depreciation, amortization and some other items, and a higher guide suggests the Business is losing money more slowly on that measure. A company can still post a per-share loss while the trend improves, which is the pattern Rivian (NASDAQ:RIVN) displayed. Revenue growth of 38 percent is large, but it comes off a smaller base, so investors will want to see whether deliveries keep rising.

Eli Lilly (NYSE:LLY): Beat with a raised revenue guide

Eli Lilly (NYSE:LLY) released third-quarter results on October 29, 2026. Revenue of USD 24.4 billion topped the USD 22.6 billion consensus by about USD 1.8 billion, a gap of roughly 8 percent that comes from simple arithmetic on two published numbers. Adjusted earnings of USD 7.48 per share beat an estimate of about USD 6.3. Management lifted 2026 revenue guidance to USD 91 billion to 92 billion. The shares closed up 6.7 percent at USD 1,374.21. Intraday gains of 4.4 percent to 6.7 percent appeared in different accounts depending on the timestamp, but the closing figure is 6.7 percent, and three published accounts confirm the results and guidance. The company release remains the primary check on every figure, and the Earnings Per Share guidance was lowered in that same release. The earnings outlook moved the other way. Adjusted earnings guidance was trimmed to USD 35 to 36 per share because acquired Research and Development charges of USD 4.57 per share are being counted. That charge is a one-time cost of buying future products, so the trimmed guide does not mean the current business is earning less.

Insmed (NASDAQ:INSM): Raised guidance, no figures

Insmed (NASDAQ:INSM) climbed 16 percent on October 29, 2026 after topping revenue expectations and raising guidance. The same day, Norwegian Cruise Line rose 13 percent after a stronger third quarter and a higher 2026 EPS guide. Only these facts are confirmed: the revenue, EPS and guidance numbers were absent from the published accounts, so this article cannot say how large either the beat or the raise was. Each direction was confirmed by a single account, a thinner standard than the two-account verification used for other names. Insmed is a biopharmaceutical company and Norwegian Cruise Line is a cruise operator, so the only link between them is the direction of their guidance. One strong day of trading does not make either stock a trend. Guidance is management's forecast for future results, and raising it tells investors that the business is tracking ahead of plan. A raise can matter more than a beat alone because it resets expectations for coming quarters, and analysts revise their models accordingly. For a commercial-stage biotech such as Insmed, growth in product sales drives revenue, while for a cruise operator, ticket pricing and onboard spending drive results.

Crocs (NASDAQ:CROX): Third raise and a HeyDude rebound

Crocs (NASDAQ:CROX) released third-quarter results on October 29, 2026, and the stock jumped about 25 percent to its highest level in more than two years. Three published accounts confirm the move and its main drivers. HeyDude, the company's second brand, lifted revenue 6.1 percent to USD 170 million, which marks its first increase in six quarters. Management also raised its 2026 outlook for a third time this year. Consensus estimates, the new guidance ranges and the figures for the main Crocs Brand were not retrieved, so none are stated here. A one-day gain of about 25 percent is large for a consumer company, which is why the shares drew attention. A brand that returns to growth after six quarters of declines changes how investors judge the business. HeyDude is the second brand, and six quarters without growth had kept attention fixed on it. A 6.1 percent rise is modest in size and comes from a small base, yet the direction matters because it suggests the brand may have stopped losing share.

Where Things Stand

In short, each company paired a better quarter with a better forecast, and investors paid for the second part. Rivian (NASDAQ:RIVN) narrowed its loss and lifted delivery guidance. Eli Lilly (NYSE:LLY) beat on revenue and earnings and raised revenue guidance. Insmed (NASDAQ:INSM) raised guidance, though the figures are missing. Crocs (NASDAQ:CROX) lifted its outlook for a third time. Gaps remain: Insmed (NASDAQ:INSM) and Crocs have no guidance ranges, and Rivian's consensus loss varies between accounts. The next catalysts are the October 30 open and the next reports. This is not Investment advice.